Reported 2 days ago
Insmed Incorporated (INSM) has experienced a significant 32% increase in its stock value over five days due to promising results from its Phase 2b trials of the pulmonary arterial hypertension (PAH) treatment, treprostinil palmitil inhalation powder (TPIP). The company plans to consult with the FDA regarding Phase 3 trials and has also submitted a New Drug Application for brensocatib aimed at treating non-cystic fibrosis bronchiectasis, with a review date set for August 2025.
Source: YAHOO